Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120892 | 0.83 | CYP11B2 (0.66) | KDM4EALDH1A1HPGDHSD17B10MTNR1A | |
| SCHEMBL7808349 | 0.81 | CYP11B1 (0.61) | KDM4EALDH1A1HPGDCYP11B2CYP11B1 | |
| SCHEMBL29954680 | 0.81 | CYP11B1 (0.61) | KDM4EALDH1A1HPGDCYP11B2CYP11B1 | |
| SCHEMBL5157844 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10CLK1 | |
| SCHEMBL1429025 | 0.77 | MTNR1A (0.47) | KDM4EALDH1A1HPGDHSD17B10MTNR1A | |
| SCHEMBL7897979 | 0.75 | CYP11B2 (0.66) | KDM4EALDH1A1HPGDHSD17B10MTNR1A | |
| SCHEMBL24393034 | 0.75 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10CLK1 | |
| SCHEMBL1429263 | 0.75 | MTNR1A (0.65) | KDM4EALDH1A1HPGDHSD17B10MTNR1A | |
| SCHEMBL4568224 | 0.73 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10MTNR1A | |
| SCHEMBL14154118 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935882-B1 | Bicyclic compounds | ASAHI KASEI PHARMA CORP (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-7598284-B2 | Indazole compounds as B3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7511069-B2 | Indazole compounds as β3 andrenoceptor agonist | ASAHI PHARMA CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1447400-B1 | BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | KDM4E 4236/4885ALDH1A1 741/4885HPGD 1430/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | KDM4E 3516/4885ALDH1A1 3711/4885HPGD 1954/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | KDM4E 4115/4885ALDH1A1 3156/4885HPGD 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.